What Happens If a Provider Adds Cannabis-Based Medicinal Products to Its Service?

The growing interest in cannabis-based medicinal products (CBMPs) in the UK private healthcare sector raises important questions for providers considering adding these treatments to their service offerings. While legal frameworks have evolved, real-world access remains complex. This post explains key factors for providers, from regulatory obligations to prescribing rules and the practical realities of patient access.

Understanding the Legal Landscape vs Real-World Access

Since November 2018, cannabis-based medicinal products are legal in the UK but only on prescription in very specific circumstances. Despite their lawful status, the reality of accessing CBMPs through routine NHS routes remains highly restrictive. Many patients turn to private providers for these treatments, where availability depends on specialist clinical judgement.

Adding CBMPs to a private healthcare service signals compliance with evolving medical standards but also carries significant operational and regulatory responsibilities. Providers need clear protocols around prescribing, pricing, and Patient Safety considerations.

The NHS Funding Gap and Private Market Reality

The NHS currently does not routinely fund most CBMP prescriptions, restricting patient access. This creates a gap that private providers often fill, offering consultations and prescribing services directly to patients willing to pay privately. However, this also means patients face substantial out-of-pocket costs.

Transparency around pricing is paramount. It is common — and concerning — that some private clinics do not clearly todaynews.co.uk state their consultation fees or prescription costs upfront. This lack of clarity can confuse patients and harm trust.

Who Can Prescribe Cannabis-Based Medicinal Products in the UK?

The rules around prescribing CBMPs are specific. Only doctors who are on the General Medical Council (GMC) Specialist Register can prescribe these products. This convention reflects the complex clinical reviews needed to assess patient suitability and the specific licensing status of CBMPs.

GPs without specialist registration generally cannot prescribe CBMPs, meaning many patients looking for these prescriptions will need to access specialist private clinics. This adds an additional layer of consideration for providers wanting to add CBMPs to their portfolio.

Regulation and CQC Oversight in England

In England, private healthcare providers offering CBMPs must navigate Care Quality Commission (CQC) regulations carefully. Importantly, if a provider intends to offer consultations involving cannabis-based medicinal prescriptions — especially if delivered via video consultations or remote prescribing — these offerings must be declared to the CQC.

Updating the Statement of Purpose

Providing CBMPs constitutes a material change in a provider’s service scope. To comply with CQC standards, providers must update their statement of purpose to include cannabis-based medicinal products. This document outlines the services and treatments offered and forms part of the formal registration details.

Notification Requirements

Providers must notify the CQC in writing about the addition of CBMPs to their services within 28 days of commencing these consultations or prescriptions. This ensures transparency and allows the CQC to update its oversight accordingly.

Video Consultations and Remote Prescribing: Opportunities and Obligations

CBMP services increasingly leverage video consultations to reach patients across wide geographic areas. Remote prescribing is often used, but this imposes strict regulatory controls.

• Video Consultations: These should maintain the same clinical standards as face-to-face appointments, including thorough patient assessment and record-keeping.
• Remote Prescribing: Prescriptions issued remotely must adhere to GMC guidance and only be done by suitably qualified specialists.

Both activities must be formally declared to the CQC in England, ensuring provider transparency and patient safety oversight.

Common Pitfalls: Pricing Transparency

One of the most common mistakes providers make when adding CBMPs is failing to state clear consultation and prescription prices. Given the high cost of CBMPs and private specialist consultations, patients need fully transparent pricing ahead of booking.

Best practice includes:

1. Publishing consultation fees clearly on the website.
2. Detailing prescription prices separately, including potential repeat prescriptions.
3. Explaining any additional fees related to video consultation or remote prescribing.
4. Clarifying whether prices cover the medication itself or only the assessment/prescribing service.

Lack of transparency can lead to patient dissatisfaction and regulatory scrutiny.

Summary Checklist for Providers Adding Cannabis-Based Medicinal Products

Requirement Details Deadline or Timing Update Statement of Purpose Include cannabis-based medicinal products explicitly in scope Before offering new service Notify CQC in Writing Inform of new CBMP prescribing/consulting Within 28 days of starting Ensure Prescribers Are GMC Specialists Only doctors on the GMC Specialist Register can prescribe CBMPs Ongoing Adhere to Video Consultation and Remote Prescribing Standards Maintain clinical standards and safety Ongoing Publish Clear Pricing Consultation and prescription fees must be publicly visible and upfront Before accepting patients

Conclusion

Adding cannabis-based medicinal products to a UK private healthcare service is more than a clinical decision — it is a regulatory, operational, and ethical commitment. Providers must carefully update their statement of purpose, notify the CQC in writing within 28 days, ensure all prescribers are GMC specialists, and maintain full transparency around pricing and patient engagement protocols.

By respecting these requirements, providers can support patient access to CBMPs responsibly, bridging the NHS funding gap while maintaining high-quality clinical care and compliance.